Now showing items 1-3 of 3

    • Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program 

      Castellano, Daniel; Antón-Aparicio, Luis M.; Esteban, Emilio; Sánchez-Hernández, Alfredo; Germá, José Ramón; Batista, Norberto; Maroto, Pablo; Pérez-Valderrama, Begoña; Luque, Raquel; Méndez-Vidal, María José (Taylor & Francis, 2014-07-07)
      [Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel. METHODS: This multi-centre ...
    • Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor 

      Lázaro Quintela, Martín; León Mateos, Luis; Vázquez Estévez, Sergio; Fernández Calvo, Ovidio; Anido Herranz, Urbano; Afonso Afonso, Francisco Javier; Santomé, Lucía; Antón-Aparicio, Luis M. (Elsevier, 2015-03)
      [Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer ...
    • Role of taxanes in advanced prostate cancer 

      Cassinello Espinosa, J.; Carballido Rodríguez, J.; Antón-Aparicio, Luis M. (Springer, 2016-02-08)
      [Abstract] Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence ...